Cyclacel Pharmaceuticals Inc (CYCC)
2.00
-0.49
(-19.68%)
USD |
NASDAQ |
May 03, 16:00
2.02
+0.02
(+1.00%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Research and Development Expense (Quarterly): 3.518M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.518M |
| September 30, 2023 | 5.236M |
| June 30, 2023 | 4.727M |
| March 31, 2023 | 5.674M |
| December 31, 2022 | 6.702M |
| September 30, 2022 | 4.413M |
| June 30, 2022 | 4.205M |
| March 31, 2022 | 4.954M |
| December 31, 2021 | 4.044M |
| September 30, 2021 | 4.217M |
| June 30, 2021 | 4.101M |
| March 31, 2021 | 2.566M |
| December 31, 2020 | 1.415M |
| September 30, 2020 | 1.075M |
| June 30, 2020 | 1.163M |
| March 31, 2020 | 1.106M |
| December 31, 2019 | 1.431M |
| September 30, 2019 | 1.063M |
| June 30, 2019 | 1.153M |
| March 31, 2019 | 1.012M |
| December 31, 2018 | 1.142M |
| September 30, 2018 | 1.205M |
| June 30, 2018 | 1.182M |
| March 31, 2018 | 0.798M |
| December 31, 2017 | 0.746M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.958M |
| June 30, 2017 | 1.222M |
| March 31, 2017 | 1.312M |
| December 31, 2016 | 1.932M |
| September 30, 2016 | 2.409M |
| June 30, 2016 | 2.637M |
| March 31, 2016 | 2.499M |
| December 31, 2015 | 2.556M |
| September 30, 2015 | 2.904M |
| June 30, 2015 | 2.58M |
| March 31, 2015 | 4.342M |
| December 31, 2014 | 4.416M |
| September 30, 2014 | 4.972M |
| June 30, 2014 | 4.545M |
| March 31, 2014 | 4.344M |
| December 31, 2013 | 2.491M |
| September 30, 2013 | 4.575M |
| June 30, 2013 | 2.631M |
| March 31, 2013 | 1.58M |
| December 31, 2012 | 1.996M |
| September 30, 2012 | 1.532M |
| June 30, 2012 | 1.717M |
| March 31, 2012 | 1.347M |
| December 31, 2011 | 2.201M |
| September 30, 2011 | 2.066M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.063M
Minimum
Sep 2019
6.702M
Maximum
Dec 2022
3.303M
Average
4.044M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Corvus Pharmaceuticals Inc | 3.999M |
| Oragenics Inc | 11.04M |
| Relmada Therapeutics Inc | 14.75M |
| Alpine Immune Sciences Inc | 22.93M |
| MAIA Biotechnology Inc | 3.717M |